Malignant histiocytosis: therapeutic results in 27 children treated with a single polychemotherapy regimen

Med Pediatr Oncol. 1989;17(3):193-6. doi: 10.1002/mpo.2950170305.

Abstract

Twenty-seven children with histologically proven malignant histiocytosis were treated in the same institution from January, 1975 to December, 1986 with a combination chemotherapy regimen containing vincristine, cyclophosphamide, doxorubicine, and prednisone. Twenty-two patients achieved complete remission, one partial remission, and four no remission. Eight patients relapsed and were treated with Lomustine (CCNU), vinblastine, and bleomycin. In seven cases, a second complete remission was obtained. The overall survival rate is 81% at 5 years and the relapse-free survival rate is 54.5% at 5 years. Prognostic factors were fever and age under 10 at diagnosis, which were correlated with a higher incidence of relapse or no remission.

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Child
  • Child, Preschool
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Lymphatic Diseases / drug therapy*
  • Lymphatic Diseases / pathology
  • Male
  • Mechlorethamine / administration & dosage
  • Prednisone / administration & dosage
  • Procarbazine / administration & dosage
  • Prognosis
  • Remission Induction
  • Vincristine / administration & dosage

Substances

  • Procarbazine
  • Mechlorethamine
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol
  • MOP protocol